Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G.

Cell Death Differ. 2018 Oct 15. doi: 10.1038/s41418-018-0213-5. [Epub ahead of print]

PMID:
30323273
2.

Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model.

Chen X, Zhou Z, Hannan R, Thomas K, Pedrosa I, Kapur P, Brugarolas J, Mou X, Wang J.

Phys Med Biol. 2018 Oct 2. doi: 10.1088/1361-6560/aae5cd. [Epub ahead of print]

PMID:
30277889
3.

Personalized Management of Advanced Kidney Cancer.

Graham J, Heng DYC, Brugarolas J, Vaishampayan U.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):330-341. doi: 10.1200/EDBK_201215.

4.

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.

Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V.

Clin Genitourin Cancer. 2018 Aug 25. pii: S1558-7673(18)30444-0. doi: 10.1016/j.clgc.2018.08.001. [Epub ahead of print]

PMID:
30217763
5.

Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back.

Elias R, Kapur P, Pedrosa I, Brugarolas J.

Clin Genitourin Cancer. 2018 Jul 20. pii: S1558-7673(18)30462-2. doi: 10.1016/j.clgc.2018.07.015. [Epub ahead of print] No abstract available.

PMID:
30100272
6.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

7.

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R.

Oncoimmunology. 2018 Mar 15;7(7):e1440168. doi: 10.1080/2162402X.2018.1440168. eCollection 2018.

PMID:
29900043
8.

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J.

Cancer Discov. 2018 Sep;8(9):1142-1155. doi: 10.1158/2159-8290.CD-17-1246. Epub 2018 Jun 8.

PMID:
29884728
9.

What is the role of nephrectomy following complete response to checkpoint inhibitors?

Woldu SL, Brugarolas J, Kapur P, Margulis V.

Urol Case Rep. 2018 Mar 14;18:60-63. doi: 10.1016/j.eucr.2018.02.016. eCollection 2018 May. No abstract available.

10.

The complex relationship between TFEB transcription factor phosphorylation and subcellular localization.

Puertollano R, Ferguson SM, Brugarolas J, Ballabio A.

EMBO J. 2018 Jun 1;37(11). pii: e98804. doi: 10.15252/embj.201798804. Epub 2018 May 15. Review.

PMID:
29764979
11.

Whole-body MRI for metastatic cancer detection using T2 -weighted imaging with fat and fluid suppression.

Wang X, Pirasteh A, Brugarolas J, Rofsky NM, Lenkinski RE, Pedrosa I, Madhuranthakam AJ.

Magn Reson Med. 2018 Oct;80(4):1402-1415. doi: 10.1002/mrm.27117. Epub 2018 Feb 14.

PMID:
29446127
12.

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK.

J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19.

PMID:
29257710
13.

Development of a Patient-specific Tumor Mold Using Magnetic Resonance Imaging and 3-Dimensional Printing Technology for Targeted Tissue Procurement and Radiomics Analysis of Renal Masses.

Dwivedi DK, Chatzinoff Y, Zhang Y, Yuan Q, Fulkerson M, Chopra R, Brugarolas J, Cadeddu JA, Kapur P, Pedrosa I.

Urology. 2018 Feb;112:209-214. doi: 10.1016/j.urology.2017.08.056. Epub 2017 Oct 19.

PMID:
29056576
14.

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.

Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS.

J Clin Oncol. 2017 Nov 10;35(32):3706-3713. doi: 10.1200/JCO.2017.73.3238. Epub 2017 Oct 4.

15.

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.

Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Kho EY, Pavía-Jiménez A, Fulkerson M, de Leon AD, Yuan Q, Dimitrov IE, Yokoo T, Ye J, Mitsche MA, Kim H, McDonald JG, Xi Y, Madhuranthakam AJ, Dwivedi DK, Lenkinski RE, Cadeddu JA, Margulis V, Brugarolas J, DeBerardinis RJ, Pedrosa I.

JCI Insight. 2017 Aug 3;2(15). pii: 94278. doi: 10.1172/jci.insight.94278. [Epub ahead of print]

16.

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).

Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC.

Kidney Cancer. 2017 Jul 26;1(1):41-47. doi: 10.3233/KCA-160002.

PMID:
30334003
17.

Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma.

Xi Y, Yuan Q, Zhang Y, Madhuranthakam AJ, Fulkerson M, Margulis V, Brugarolas J, Kapur P, Cadeddu JA, Pedrosa I.

Eur Radiol. 2018 Jan;28(1):124-132. doi: 10.1007/s00330-017-4925-6. Epub 2017 Jul 5.

PMID:
28681074
18.

Correction for Wolff et al., "Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia".

Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J.

Mol Cell Biol. 2017 Jun 15;37(13). pii: e00224-17. doi: 10.1128/MCB.00224-17. Print 2017 Jul 1. No abstract available.

19.

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.

Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):91-100. doi: 10.1016/j.ijrobp.2017.01.032.

20.

Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, Madhuranthakam AJ, Pedrosa I, Wang T, Dey A, Busslinger M, Xie XJ, Hammer RE, McKay RM, Kapur P, Brugarolas J.

Cancer Discov. 2017 Aug;7(8):900-917. doi: 10.1158/2159-8290.CD-17-0292. Epub 2017 May 4.

21.

Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver.

Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J, DeBose-Boyd RA.

J Biol Chem. 2017 Jun 2;292(22):9382-9393. doi: 10.1074/jbc.M117.788562. Epub 2017 Apr 17.

22.

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS.

BMC Urol. 2017 Mar 21;17(1):19. doi: 10.1186/s12894-017-0209-3.

23.

Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer.

Bowman IA, Pedrosa I, Kapur P, Brugarolas J.

Clin Genitourin Cancer. 2017 Aug;15(4):e675-e680. doi: 10.1016/j.clgc.2017.01.026. Epub 2017 Feb 6.

24.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
25.

Multistep regulation of TFEB by MTORC1.

Vega-Rubin-de-Celis S, Peña-Llopis S, Konda M, Brugarolas J.

Autophagy. 2017 Mar 4;13(3):464-472. doi: 10.1080/15548627.2016.1271514. Epub 2017 Jan 5.

26.

Targeting renal cell carcinoma with a HIF-2 antagonist.

Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J.

Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5.

27.

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned.

Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V.

BMC Urol. 2016 Jul 19;16(1):43. doi: 10.1186/s12894-016-0157-3.

28.

Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.

Brugarolas J.

J Natl Compr Canc Netw. 2016 Jul;14(7):925-7. No abstract available.

PMID:
27407131
29.

Hepatic mTORC1 Opposes Impaired Insulin Action to Control Mitochondrial Metabolism in Obesity.

Kucejova B, Duarte J, Satapati S, Fu X, Ilkayeva O, Newgard CB, Brugarolas J, Burgess SC.

Cell Rep. 2016 Jul 12;16(2):508-519. doi: 10.1016/j.celrep.2016.06.006. Epub 2016 Jun 23.

30.

Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity.

Yuan Q, Kapur P, Zhang Y, Xi Y, Carvo I, Signoretti S, Dimitrov IE, Cadeddu JA, Margulis V, Brugarolas J, Madhuranthakam AJ, Pedrosa I.

Clin Genitourin Cancer. 2016 Dec;14(6):e585-e594. doi: 10.1016/j.clgc.2016.04.007. Epub 2016 Apr 22.

31.

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Tran TA, Leong HS, Pavia-Jimenez A, Fedyshyn S, Yang J, Kucejova B, Sivanand S, Spence P, Xie XJ, Peña-Llopis S, Power N, Brugarolas J.

Mol Cell Biol. 2016 Jun 15;36(13):1836-55. doi: 10.1128/MCB.00189-16. Print 2016 Jul 1.

32.

Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, Lotan Y, Brugarolas J, He D, Hsieh JT.

Oncogene. 2016 Sep 1;35(35):4663-74. doi: 10.1038/onc.2016.4. Epub 2016 Feb 15.

PMID:
26876207
33.

Inhibition de l'extravasation des cellules de carcinomes rénaux à cellules claires par la dysregulation de la formation des invadopodes, via l'inbihition de PAK1.

Mazzola C, Williams K, Brugarolas J, Power N, Chambers A, Leong H.

Prog Urol. 2015 Nov;25(13):801-2. doi: 10.1016/j.purol.2015.08.171. French. No abstract available.

PMID:
26544365
34.

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2016 Jan;29(1):34-42. doi: 10.1038/modpathol.2015.123. Epub 2015 Oct 30.

35.

Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β-Catenin.

Kim H, Rodriguez-Navas C, Kollipara RK, Kapur P, Pedrosa I, Brugarolas J, Kittler R, Ye J.

Cell Rep. 2015 Oct 20;13(3):495-503. doi: 10.1016/j.celrep.2015.09.010. Epub 2015 Oct 8.

36.

Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.

Zhang Y, Kapur P, Yuan Q, Xi Y, Carvo I, Signoretti S, Dimitrov I, Cadeddu JA, Margulis V, Muradyan N, Brugarolas J, Madhuranthakam AJ, Pedrosa I.

Clin Genitourin Cancer. 2016 Feb;14(1):e25-36. doi: 10.1016/j.clgc.2015.08.007. Epub 2015 Aug 29.

37.

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113. Epub 2015 Aug 20.

38.

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.

Wolff NC, Pavía-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A, Xie XJ, Williams NS, Kapur P, Posner B, McKay RM, Brugarolas J.

Oncotarget. 2015 Jul 10;6(19):16951-62.

39.

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome.

Denard B, Pavia-Jimenez A, Chen W, Williams NS, Naina H, Collins R, Brugarolas J, Ye J.

PLoS One. 2015 Jun 25;10(6):e0129233. doi: 10.1371/journal.pone.0129233. eCollection 2015.

40.

Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.

Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J.

BMC Urol. 2015 Apr 3;15:24. doi: 10.1186/s12894-015-0019-4.

41.

Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus.

Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Choy H, Brugarolas J, Timmerman RD.

Cancer Biol Ther. 2015;16(5):657-61. doi: 10.1080/15384047.2015.1026506.

42.

Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.

Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J.

Clin Genitourin Cancer. 2015 Aug;13(4):e321-3. doi: 10.1016/j.clgc.2014.12.007. Epub 2014 Dec 20. No abstract available.

PMID:
25620636
43.

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS.

Urol Oncol. 2015 Jan;33(1):23.e9-23.e14. doi: 10.1016/j.urolonc.2014.10.014. Epub 2014 Nov 24.

44.

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S.

Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17.

45.

Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.

Wang SS, Gu YF, Wolff N, Stefanius K, Christie A, Dey A, Hammer RE, Xie XJ, Rakheja D, Pedrosa I, Carroll T, McKay RM, Kapur P, Brugarolas J.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16538-43. doi: 10.1073/pnas.1414789111. Epub 2014 Oct 30.

46.

Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing.

Pavía-Jiménez A, Tcheuyap VT, Brugarolas J.

Nat Protoc. 2014 Aug;9(8):1848-59. doi: 10.1038/nprot.2014.108. Epub 2014 Jul 10.

47.

Molecular genetics of clear-cell renal cell carcinoma.

Brugarolas J.

J Clin Oncol. 2014 Jun 20;32(18):1968-76. doi: 10.1200/JCO.2012.45.2003. Epub 2014 May 12.

48.

REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.

Wolff NC, McKay RM, Brugarolas J.

Mol Cancer Res. 2014 Jun;12(6):867-77. doi: 10.1158/1541-7786.MCR-13-0625. Epub 2014 Mar 10.

49.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A.

Cancer. 2014 Apr 1;120(7):1059-67. doi: 10.1002/cncr.28521. Epub 2013 Dec 30. Erratum in: Cancer. 2014 Jun 1;120(11):1752-3.

50.

Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.

Peña-Llopis S, Brugarolas J.

Nat Protoc. 2013 Nov;8(11):2240-55. doi: 10.1038/nprot.2013.141. Epub 2013 Oct 17.

Supplemental Content

Loading ...
Support Center